By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Reaction Biology has reeled in a $1.2 million small business innovation research grant from the National Cancer Institute that it will use to expand an epigenetics-related drug discovery screening platform, the company said today.

The Malvern, Pa.-based firm plans to use the two-year grant to expand its Methyltransferase HotSpotSM drug discovery screens from 14 to 35 or more, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.